The U.S. Food and Drug Administration approves Moderna’s seasonal influenza vaccine, described across reports as the first licensed flu shot to use messenger RNA (mRNA) technology. Multiple outlets report that the approval is granted by the FDA on Wednesday, making Moderna’s product the first U.S. flu vaccine built on mRNA. NBC News identifies the product as mFlusiva, while other coverage refers to it more generally as Moderna’s mRNA flu vaccine or mRNA seasonal flu vaccine. The approvals mark a milestone because mRNA vaccines use instructions that prompt cells to produce an immune-stimulating target, rather than delivering a traditional flu vaccine component. The reports do not provide additional details about the vaccine’s dosing, clinical results, target strains, or distribution plans beyond confirming FDA authorization and that it is the first flu shot in the U.S. to use the technology. Overall, the sources agree that the FDA’s decision grants permission for Moderna’s mRNA flu vaccine to be used in the U.S. following regulatory review.